Please login to the form below
acute myeloid leukemia
This page shows the latest acute myeloid leukemia news and features for those working in and with pharma, biotech and healthcare.
bluebird bio says AML case "very unlikely" to be related to gene therapy LentiGlobin
bluebird bio has announced that a recently reported suspected unexpected serious adverse reaction (SUSAR) of acute myeloid leukemia (AML) is "very unlikely" to be related to its sickle cell disease (SCD)
Latest news
-
Astellas’ Xospata scores positive CHMP recommendation
The FLT3 inhibitor received the positive opinion for use as a monotherapy in the treatment of relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutation. ... 2017. AML is the most common form of acute leukaemia in adults and has a low
-
Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial
UCART123 is a gene-edited CAR-T cell therapy that targets CD123 and will be tested in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
-
Pfizer's SMO inhibitor boosts survival in blood cancer trial
Glasdegib (previously known as PF-04449913) extended overall survival in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) to almost nine months when added to low-dose ... indications such as MDS, acute lymphoblastic
-
AbbVie and Roche's leukaemia drug venetoclax nears EU market
AbbVie and Roche believe that venetoclax will be effective across a range of blood cancers, and are testing the drug in acute myeloid leukemia, non-Hodgkin's lymphoma, and multiple myeloma
-
NICE rejects Celgene's Vidaza for leukaemia
The National Institute for Health and Care Excellence (NICE) has turned down Celgene's Vidaza to treat older people with acute myeloid leukemia (AML) in final draft guidance.
Astellas’ Xospata scores positive CHMP recommendation
Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial
Pfizer's SMO inhibitor boosts survival in blood cancer trial
AbbVie and Roche's leukaemia drug venetoclax nears EU market
NICE rejects Celgene's Vidaza for leukaemia
More from news
Approximately 1 fully matching, plus 8 partially matching documents found.
Latest from PMHub
-
Acute leukaemia patients get new online information centre that will help them get the best possible care
a-kind educational resource centre that provides acute leukaemia patients with the support they need, when they need it most. ... Some of the world's leading experts in the treatment of acute lymphoblastic leukaemia (ALL) and acute myeloid
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Publications Director
-
Competitive Salary
- Account Director, Publications, Opthalmology, Medical Communicat...
-
Highly competitive salary
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, Patient Engagement & Solutions, Lo...
-
Highly competitive salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
-
Planner
-
Salary TBC
- Senior Account Director, Publications, Opthalmology, Medical Com...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Publications, Women’s health, Medical C...
-
Highly competitive salary
- Group Account Director, Patient Engagement & Solutions, Lond...
-
Highly competitive salary
- Senior Medical Writer, Rare diseases, Medical Communications age...
-
Highly competitive salary
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Senior Account Manager
-
Salary TBC
- Pfizer/BioNTech, AZ vaccines effective against Delta COVID-19 variant after two doses
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Novartis highlights potential of its radioligand therapy in prostate cancer at ASCO
- Disappointing results from CureVac’s COVID-19 vaccine as phase 2/3 study shows only 47% efficacy
- Sanofi’s C1s inhibitor sutimlimab hits the mark in late-stage CAD study
- AZ, Pfizer/BioNTech COVID-19 vaccines 'highly effective' against Indian variant
- Court rules on AZ and EU’s COVID-19 vaccine dispute
- BMS and Eisai to collaborate in deal worth up to $3.1bn
- US announces $3bn funding boost for antiviral COVID-19 treatments
- Biogen doses first patient in phase 3 systemic lupus erythematosus study
- Kite partners with Shoreline Biosciences to develop allogeneic cell therapies
- ‘Funny’, ha ha: how neurodiverse comedy can help us understand each other
- BeiGene’s reveals positive data for Brukinsa in head-to-head Imbruvica trial
- Merck signs $1.2bn supply deal with US government for Molnupiravir
- AZ, Pfizer/BioNTech COVID-19 vaccines 'highly effective' against Indian variant
- Sanofi, GSK begin enrolment for phase 3 COVID-19 vaccine study
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Sense of belonging
PMHub
Havas Lynx Group
We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...
Latest intelligence
- How early-stage clinical research is facilitating the new wave of personalised medicines
- By Jorg Taubel...
- Patient diversity in clinical trials needs to be centre stage
- By Danny Buckland...
- Why empathy in digital patient recruitment is vital
- This is where empathy mapping can be incredibly effective....
